Receptor for hyaluronan acid–mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia

Greiner, Jochen; Ringhoffer, Mark; Taniguchi, M; Schmitt, Anita; Kirchner, Dieter; Krähn, Gertraud; Heilmann, V.; Gschwend, Jürgen E.; Bergmann, Lothar; Döhner, Hartmut; Schmitt, Michael

doi:10.1016/s0301-472x(02)00874-3

Cited by 135 publications

(132 citation statements)

References 45 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…16 This peptide sequence also encompasses the HLA-DP5-restricted WT1 337-347 epitope 70 as well as the WT1 333-347 epitope, which can be recognized by CD4 þ regulatory T cells in the context of HLA-DR4. 71 Other WT1 helper epitopes with direct relevance to AML immunotherapy are WT1 427-445 and WT1 [122][123][124][125][126][127][128][129][130][131][132][133][134][135][136][137][138][139][140] . 69 The latter contains another immunogenic CD4 þ T-cell epitope, WT1 [124][125][126][127][128][129][130][131][132][133][134][135][136][137][138] , and the HLA-A*0201-restricted CD8 þ T-cell epitope, WT1 [126][127][128][129][130][131][132][133][134] , 16 and is thus capable of stimulating a combined CD8 þ /CD4 þ WT1-specific T-cell immune response.…”

Section: Criterion 4: Immunogenicity Humoral and Cellular Immune Respmentioning

confidence: 99%

Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

2012

View full text Add to dashboard Cite

The graft-versus-leukemia effect of allogeneic hematopoietic stem cell transplantation (HSCT) has shown that the immune system is capable of eradicating acute myeloid leukemia (AML). This knowledge, along with the identification of the target antigens against which antileukemia immune responses are directed, has provided a strong impetus for the development of antigen-targeted immunotherapy of AML. The success of any antigen-specific immunotherapeutic strategy depends critically on the choice of target antigen. Ideal molecules for immune targeting in AML are those that are: (1) leukemia-specific; (2) expressed in most leukemic blasts including leukemic stem cells; (3) important for the leukemic phenotype; (4) immunogenic; and (5) clinically effective. In this review, we provide a comprehensive overview on AML-related tumor antigens and assess their applicability for immunotherapy against the five criteria outlined above. In this way, we aim to facilitate the selection of appropriate target antigens, a task that has become increasingly challenging given the large number of antigens identified and the rapid pace at which new targets are being discovered. The information provided in this review is intended to guide the rational design of future antigen-specific immunotherapy trials, which will hopefully lead to new antileukemia therapies with more selectivity and higher efficacy.

show abstract

Section: Criterion 4: Immunogenicity Humoral and Cellular Immune Respmentioning

confidence: 99%

Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

2012

View full text Add to dashboard Cite

show abstract

“…17 Moreover, in AML, CML, and renal cell carcinoma patients, RHAMM FL expression was accompanied with RHAMM Ϫexon4 expression, while RHAMM Ϫexon13 was undetectable. 18 We thus investigated the differential expression of RHAMM Ϫexon4 and RHAMM FL within single MM PCs.…”

Section: Rhamm Isoforms Are Rarely Coexpressed In Individual MM Plasmmentioning

confidence: 99%

“…15 While RHAMM is ubiquitously expressed in murine tissues (with elevated expression in testis, thymus, and spleen), 16 consistent detection of RHAMM expression within healthy human tissues appears to be limited to the testis. 17,18 Reports of RHAMM expression have identified the testis, spleen, colon, and stomach 17 ; the testis, placenta, and thymus 18 ; and the testis, placenta, lung, and pancreas 19 as RHAMMpositive tissues (in decreasing orders). RHAMM expression is rare in normal peripheral blood 7,17,18 and purified CD19 ϩ7 or CD34 ϩ peripheral blood mononuclear cells (PBMCs).…”

Section: Introductionmentioning

confidence: 99%

“…17,18 Reports of RHAMM expression have identified the testis, spleen, colon, and stomach 17 ; the testis, placenta, and thymus 18 ; and the testis, placenta, lung, and pancreas 19 as RHAMMpositive tissues (in decreasing orders). RHAMM expression is rare in normal peripheral blood 7,17,18 and purified CD19 ϩ7 or CD34 ϩ peripheral blood mononuclear cells (PBMCs). 19 RHAMM expression influences tumor progression and metastasis in melanoma, pancreatic, breast, and endometrial carcinomas, [20][21][22][23] and RHAMM is detected as a tumorassociated antigen in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), 18 and colon cancer.…”

Section: Introductionmentioning

confidence: 99%

“…RHAMM expression is rare in normal peripheral blood 7,17,18 and purified CD19 ϩ7 or CD34 ϩ peripheral blood mononuclear cells (PBMCs). 19 RHAMM expression influences tumor progression and metastasis in melanoma, pancreatic, breast, and endometrial carcinomas, [20][21][22][23] and RHAMM is detected as a tumorassociated antigen in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), 18 and colon cancer. 17 A splice variant of exon 4, RHAMM Ϫexon4 (RHAMM Ϫ48 ), has been described in myeloma patients and in diverse tumors and cancer cell lines.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations